From: Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease
Characteristic | Low IL-15 level, <0.64 pg/ml (n = 33) |  | Intermediate IL-15 level, 0.64–0.88 pg/ml (n = 15) |  | High IL-15 level, >0.88 pg/ml (n = 13) |  |
---|---|---|---|---|---|---|
Female/male | 29/4 | (88/12) | 11/4 | (73/27) | 10/3 | (77/23) |
Age at onset (years) | 52 | (45–57) | 48 | (45–54) | 57 | (53–61) |
Disease duration (months) | 19 | (13–28) | 16 | (11–25) | 11 | (8–21) |
Clinical features | Â | Â | Â | Â | Â | Â |
   Skin score (points) | 9 | (4–14) | 11 | (4–17) | 15 | (8–21) |
   Diffuse cutaneous systemic sclerosis/limited cutaneous systemic sclerosis | 8/25 | (24/76) | 3/12 | (20/80) | 6/7 | (46/54) |
   Pitting scars or ulcer | 9 | (27) | 6 | (40) | 3 | (23) |
   Telangiectasis | 9 | (27) | 6 | (40) | 1 | (8) |
   Calcinosis | 6 | (18) | 5 | (33) | 5 | (38) |
Organ involvement | Â | Â | Â | Â | Â | Â |
   Oesophagus | 20 | (61) | 11 | (73) | 10 | (77) |
   Lung (radiological) | 7 | (21) | 2 | (13) | 4 | (31) |
   Heart | 5 | (15) | 4 | (27) | 4 | (31) |
   Kidney | 1 | (3) | 1 | (7) | 0 | (0) |
   Muscle | 1 | (3) | 2 | (13) | 1 | (8) |
   Joint | 5 | (15) | 1 | (7) | 0 | (0) |
Lung function tests | Â | Â | Â | Â | Â | Â |
   Vital capacity (p%) | 94 | (85–103) | 94 | (84–105) | 75 | (66–89)* |
   Diffusing capacity for carbon monoxide (p%) | 84 | (77–97) | 71 | (60–87)†| 70 | (62–81)‡ |
Serological findings | Â | Â | Â | Â | Â | Â |
   Antinuclear antibodies | 21 | (64) | 14 | (93) | 11 | (85) |
   Anti-scleroderma-70 antibodies | 6 | (18) | 4 | (27) | 2 | (15) |
   Anticentromer antibodies | 10 | (30) | 2 | (13) | 2 | (15) |
Laboratory findings | Â | Â | Â | Â | Â | Â |
   Erythrocyte sedimentation rate (mm/hour) | 17 | (10–27) | 12 | (8–22) | 12 | (6–18) |
   C-reactive protein (mg/l) | 0 | (0–6) | 0 | (0–8) | 1.6 | (0–8.1) |
   Orosomucoid (g/l) | 0.8 | (0.68–0.91) | 0.86 | (0.77–0.96) | 0.85 | (0.80–1.11) |
   IgG (g/l) | 10.9 | (9.5–14.6) | 9.5 | (7.6–12.2) | 12.6 | (9.6–15.1) |